1. Home
  2. ATHM vs AUPH Comparison

ATHM vs AUPH Comparison

Compare ATHM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ATHM

Autohome Inc.

HOLD

Current Price

$17.78

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.88

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATHM
AUPH
Founded
2008
1993
Country
China
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
ATHM
AUPH
Price
$17.78
$15.88
Analyst Decision
Hold
Buy
Analyst Count
1
4
Target Price
$28.00
$17.25
AVG Volume (30 Days)
710.2K
1.1M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
9.83%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
0.25
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$17.54
Revenue Next Year
$4.77
$15.74
P/E Ratio
$12.13
$63.40
Revenue Growth
N/A
20.38
52 Week Low
$15.57
$7.29
52 Week High
$29.92
$16.88

Technical Indicators

Market Signals
Indicator
ATHM
AUPH
Relative Strength Index (RSI) 51.59 52.74
Support Level $16.22 $14.60
Resistance Level $18.81 $16.38
Average True Range (ATR) 0.83 0.54
MACD 0.09 0.03
Stochastic Oscillator 72.84 50.43

Price Performance

Historical Comparison
ATHM
AUPH

About ATHM Autohome Inc.

Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: